Older NIH announcements

roloffl — Mon, 08 Jun 2026 19:13:34 +0000

Older NIH announcements roloffl Mon, 06/08/2026 - 2:13 pm

NIH has re-enabled the no-cost extension functionality within eRA Commons. Recipients may resume initiating first no-cost extensions in eRA Commons.

Read notice.

Starting Oct. 1, 2025, NIH grant recipients must provide training for faculty and researchers identified as senior/key personnel on the agency's new policy requirement to disclose all research activities and affiliations (active and pending) in the "other support" section of grant applications. See other support form.

The Division of Research is developing plans to comply with this policy and will be communicating with the grants community.

Read notice.

The agency is providing guidance on the appropriate use of AI to in proposals to maintain the fairness and originality of the NIH research application process.

NIH also is instituting a new policy limiting the number of new, renewal, resubmission and revision applications that principal investigators can submit in a calendar year.

Read notice

The expansion is part of a broader initiative to prioritize human-based research and reduce reliance on animal models. Make sure to carefully read current and upcoming NIH funding opportunities for NAMs-related criteria.

Guidance from Mizzou's Division of Research, Innovation and Impact

NIH issued a short-term extension to the early-stage investigator eligibility period.

This extension addresses delays impacting grant application submissions, peer review or award processing timelines between Jan. 1, 2025, and May 31, 2025, and seeks to mitigate their effects on the biomedical research community.

Read notice.

Keep on top of the latest changes affecting NIH grants administration and funding by bookmarking this page, which is updated as new information becomes available.

NIH has removed the automatic no-cost extension (NCE) feature from their website. All NCEs must now be requested via the prior approval module.

Read notice.

On May 5, 2025, the White House Executive Action on Biological Research directed federal agencies to end funding for “dangerous gain-of-function research” and develop a new oversight policy within 120 days. In response, the NIH released an updated notice on May 7, 2025, rescinding their previous DURC-PEPP policy implementation guidance. Other federal funding agencies have not yet published updated guidance. The DURC program oversees life sciences research that could be misused to harm public health or national security.

MU will continue to monitor developments and update the Institutional Biosafety Committee homepage as new information becomes available.

NIH is updating its policy and practice on issuing foreign subawards.

The new policy will prohibit foreign subawards from being nested under the parent grant.
This new award structure will allow NIH to track the project’s funds individually, while scientific progress will be reported collectively by the primary institution, under the Research Performance Progress Report.
NIH anticipates implementing the new award structure by Sept. 30, 2025 (before fiscal year 2026).

Effective May 1, 2025, and until the details of the new foreign collaboration award structure are released, NIH will not issue awards to domestic or foreign entities (new, renewal or non-competing continuation) that include a subaward to a foreign entity.

Please note: PIs can eliminate the foreign subaward during this time, and funding will continue.

Read notice. | Read article.

The U.S. Department of Health and Human Services and the NIH have announced a universal vaccine platform called Generation Gold Standard developed by NIH’s National Institute of Allergy and Infectious Diseases to create broad-spectrum vaccines targeting multiple pandemic-prone viruses like avian influenza (H5N1) and coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS-CoV).

The initiative aims to improve pandemic preparedness and vaccine effectiveness by focusing on long-lasting, cross-strain protection, beyond current virus strains. Key components of this platform include:

BPL-inactivated whole-virus vaccines that preserve the virus's structure while preventing infectivity, generating strong immune responses (B and T cells), and offering protection across various virus families
Intranasal formulation of the BPL-1357 vaccine, which is designed to block virus transmission and is currently in advanced clinical trials, on track for FDA review by 2029
Increased government-led transparency and the elimination of commercial conflicts of interest

The BPL platform could be adapted for future vaccines against other respiratory viruses. Clinical trials for universal influenza vaccines are set to begin in 2026, with FDA approval targeted for 2029.

Read announcement.

NIH announced the compliance date for the revised public access policy will move up by six months, from Dec. 31, 2025, to July 1, 2025. All other aspects of the 2024 public access policy remain the same.

NIH Director Jay Bhbattacharya issued a statement detailing the benefits of the change.

Read notice.

Sponsored Programs Administration received communication from NIH requesting the early submission of Research Performance Progress Reports (RPPRs ) to allow for processing time of notice of awards. We encourage PIs to submit their RPPRs two months prior to the end date.

NIH announced its initiative to reduce the use of animals in NIH-funded research. This follows the FDA roadmap released in April, which discussed collaboration with the NIH.

NIH Director Bhattacharya emphasized that innovations such as organoids, tissue chips and computational models allow for more accurate human-centric research, potentially improving health care outcomes and accelerating the development of treatments.

As part of the initiative, the NIH will establish the Office of Research Innovation, Validation and Application (ORIVA) to oversee these efforts. ORIVA will focus on promoting non-animal research methods, increasing funding, and ensuring their integration into NIH's broader biomedical research programs.

Read announcement.

NIH issued a notice that fund recipients must comply with all applicable federal anti-discrimination laws material to the government’s payment decisions. This term applies prospectively to new, renewal, supplement or continuation awards issued on or after April 21, 2025.

By accepting grant awards, recipients certify that:

They do not, and will not during the term of the financial assistance award, operate any programs that advance or promote DEI, DEIA or discriminatory equity ideology in violation of federal anti-discrimination laws.
They do not engage in and will not, during the term of the award, engage in a discriminatory prohibited boycott, as defined in the notice.

The NIH reserves the right to terminate financial assistance awards and recover all funds if recipients operate any program that violates federal anti-discriminatory laws or engage in a prohibited boycott.

Note: The notice applies only to grant award “recipients,” which the NIH defines as the entity that receives the NIH grant award.

Read notice.

Spurring Tiger research momentum

roloffl — Mon, 01 Jun 2026 21:20:45 +0000

Spurring Tiger research momentum roloffl Mon, 06/01/2026 - 4:20 pm

Small objects, big stories

ethridgea — Mon, 01 Jun 2026 16:42:10 +0000

Small objects, big stories ethridgea Mon, 06/01/2026 - 11:42 am

Healthy growth for Mizzou influenza research

meissenr — Thu, 28 May 2026 18:59:19 +0000

Healthy growth for Mizzou influenza research meissenr Thu, 05/28/2026 - 1:59 pm

Empowering veterans with business know-how

roloffl — Wed, 27 May 2026 13:31:18 +0000

Empowering veterans with business know-how roloffl Wed, 05/27/2026 - 8:31 am

What’s in a mouse name?

meissenr — Fri, 22 May 2026 13:52:45 +0000

What’s in a mouse name? meissenr Fri, 05/22/2026 - 8:52 am

A new wave of ideas go to market

roloffl — Fri, 01 May 2026 13:28:53 +0000

A new wave of ideas go to market roloffl Fri, 05/01/2026 - 8:28 am

Beauty through the scope

meissenr — Thu, 30 Apr 2026 20:48:16 +0000

Beauty through the scope meissenr Thu, 04/30/2026 - 3:48 pm

Accelerating IRB approvals

roloffl — Wed, 29 Apr 2026 17:53:52 +0000

Accelerating IRB approvals roloffl Wed, 04/29/2026 - 12:53 pm

From poster presenter to judge

ethridgea — Wed, 22 Apr 2026 16:38:24 +0000

From poster presenter to judge ethridgea Wed, 04/22/2026 - 11:38 am

Research, Innovation & Impact

Older NIH announcements

Related Links

Spurring Tiger research momentum

Small objects, big stories

Healthy growth for Mizzou influenza research

Empowering veterans with business know-how

What’s in a mouse name?

A new wave of ideas go to market

Beauty through the scope

Accelerating IRB approvals

From poster presenter to judge